[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611146":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":52,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"China-Japan Friendship Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","3±1 days before the operation, intravenous infusion of isomaltose iron injection was administered. The dosage was in accordance with the drug instructions. The maximum single infusion dose was 20mg\u002Fkg. If the dose could not be made up in one infusion, the remaining dose should be made up every other week.",[13],"Drug: Iron Isomaltoside injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","At the same time point, the same dose of physiological saline was infused.",[19],"Drug: Physiological saline solution (as placebo)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Iron Isomaltoside injection","Patients in the isomaltan iron group received intravenous isomaltan iron dissolved in 250 ml of normal saline 3 days prior to surgery. The patients' iron requirements were calculated using a simplified scale, with a maximum single dose of 20 mg\u002Fkg. If the dose was insufficient in a single administration, a second infusion was required every other week. The placebo group received an equal volume of 0.9% normal saline.\n\nSimplified scale:\n\nHemoglobin (g\u002FL) patient weight \\\u003C50kg 50-70kg \\>70kg\n\n≥100 500mg 1000mg 1500mg \\\u003C100 500mg 1500mg 2000mg",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Physiological saline solution (as placebo)","At the same time point, the same dose of physiological saline was infused as the experimental group.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Nianrong Zhang Zhang","CONTACT","+86 188 1048 8650","znrsd@163.com",[38],{"facility":5,"status":39,"city":40,"state":26,"zip":26,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Beijing","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":34,"phone":35,"phoneExt":26,"email":36},"Nianrong Zhang",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Hua Meng","Director of the General Surgery Department & Obesity and Metabolic Disease Center of China-Japan Friendship Hospital","100611146","study-on-supplement-of-intravenous-ferric-derisomaltose-to-prevent-anemia-and-improve-the-quality-of-life-in-obese-patients-with-iron-deficiency-100611146",false,"NCT07236788","Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency.","Inclusion Criteria:\n\n* ① Baseline Hb: Men 10-14 g\u002FdL, Women 10-13 g\u002FdL; ② Iron deficiency: Serum ferritin (SF) \\\u003C100 μg\u002FL, and transferrin saturation (TSAT) \\\u003C20%; ③ BMI \\>30 kg\u002Fm2.\n\nExclusion Criteria:\n\n* ① Known severe hypersensitivity reactions to other parenteral iron supplements; ② Mean corpuscular volume (MCV) \\> 100 fL; ③ Received intravenous iron infusion within the past 3 months; ④ Concurrent tumors; ⑤ Concurrent iron overload or other hematologic disorders; ⑥ Concurrent infectious diseases such as hepatitis B; ⑦ Moderately impaired liver function: decompensated cirrhosis or hepatitis, ALT, AST \\> 3 × upper limit of normal (ULN); ⑧ Concurrent acute or chronic infections, heart failure, or other diseases affecting iron metabolism; ⑨ Patients with stage 3 or higher chronic renal insufficiency: glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin; ⑩ Pregnant or lactating women; ⑪ Acute infections, rheumatoid arthritis, or significant joint inflammation.","ALL","18 Years","65 Years",{"count":66,"type":67},200,"ESTIMATED","INTERVENTIONAL",[70],"NA","This study aimed to explore the effects of preoperative intravenous isomaltose iron supplementation versus placebo on postoperative Hb improvement, prevention of postoperative anemia, and improvement in quality of life in patients undergoing bariatric surgery.",[73,74,75,76],"Obesity","Anemia","Iron Deficiencies","Bariatric Surgery","2025-11-15",{"date":79,"type":80},"2025-11-19","ACTUAL",{"date":82,"type":80},"2025-03-01",{"date":84,"type":67},"2027-03-30",{"name":5,"class":6},1]